{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:06:53Z","timestamp":1780607213846,"version":"3.54.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Soci\u00e9t\u00e9 Francophone de N\u00e9phrologie, Dialyse et Transplantation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vasopressin, a hormone regulating water metabolism, has been poorly studied in patients on peritoneal dialysis (PD). Vasopressin measurement is challenging and not routinely available in clinical practice. This study aimed to evaluate whether copeptin, a stable surrogate marker of vasopressin, could be used to assess vasopressin levels in patients on PD and to determine if vasopressin maintains its antidiuretic effect in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 34 PD patients from three French nephrology centers. Plasma vasopressin was measured using radioimmunoassay, while copeptin was quantified with a non-competitive immunofluorescence assay. Urine osmolality and 24-hour urine output were assessed, and peritoneal adequacy tests were performed. Associations between copeptin, vasopressin, and clinical parameters were analyzed using Spearman correlations and mixed-effect models. Healthy controls were included for comparison.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Copeptin levels were strongly correlated with vasopressin levels (Spearman's rho = 0.62, P &amp;lt; 0.001), confirming its reliability as a biomarker of vasopreassin. Higher copeptin levels were associated with increased urine osmolality (\u03b2 = 3.63, P = 0.008) and decreased 24-hour urine output (\u03b2 = \u22120.53, P = 0.008), indicating that vasopressin retains its antidiuretic activity in PD patients. Compared to healthy controls, PD patients had lower urine osmolality and required higher copeptin levels to achieve similar urine concentration, suggesting vasopressin resistance. Copeptin levels were also associated with lower residual kidney function and higher brain natriuretic peptide levels but were not influenced by blood pressure, plasma sodium, or PD characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides evidence that vasopressin maintains an antidiuretic effect in PD patients, and supports the use of copeptin as a robust biomarker for vasopressin in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajaf021","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:24:05Z","timestamp":1770218645000},"page":"151-159","source":"Crossref","is-referenced-by-count":0,"title":["Copeptin is a reliable biomarker of vasopressin and\u00a0is associated with urine osmolality in patients on\u00a0peritoneal dialysis"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-6332","authenticated-orcid":false,"given":"Adrien","family":"Flahault","sequence":"first","affiliation":[{"name":"Department of Nephrology, Dialysis and Transplantation, Centre Hospitalier R\u00e9gional Universitaire de Nancy , Nancy ,","place":["France"]},{"name":"Universit\u00e9 de Lorraine, Inserm, UMR INSPIIRE, Inserm , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Keck","sequence":"additional","affiliation":[{"name":"D\u00e9partement M\u00e9dicaments et Technologies pour la Sant\u00e9 (DMTS), Universit\u00e9 Paris-Saclay, CEA, INRAE, SIMoS , Gif-sur-Yvette 91191 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Kersraoui","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, H\u00f4pitaux de Saint Maurice , Saint Maurice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Beaudreuil","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Transplantation, CHU Bic\u00eatre , facult\u00e9 Paris-Sud, Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immaculada","family":"Gomez Alvarez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Transplantation, H\u00f4pital Europ\u00e9en Georges Pompidou (HEGP)-Assistance Publique H\u00f4pitaux de Paris (APHP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Barbe","sequence":"additional","affiliation":[{"name":"D\u00e9partement M\u00e9dicaments et Technologies pour la Sant\u00e9 (DMTS), Universit\u00e9 Paris-Saclay, CEA, INRAE, SIMoS , Gif-sur-Yvette 91191 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Monique","family":"Nuyt","sequence":"additional","affiliation":[{"name":"CHU Sainte-Justine, Research Center , Montr\u00e9al, QC H3T 1C5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9loise","family":"Brian\u00e7on","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Transplantation, H\u00f4pital Europ\u00e9en Georges Pompidou (HEGP)-Assistance Publique H\u00f4pitaux de Paris (APHP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Thervet","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Transplantation, H\u00f4pital Europ\u00e9en Georges Pompidou (HEGP)-Assistance Publique H\u00f4pitaux de Paris (APHP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Baron","sequence":"additional","affiliation":[{"name":"Department of Physiology, H\u00f4pital Europ\u00e9en Georges Pompidou (HEGP)-Assistance Publique H\u00f4pitaux de Paris (APHP) , Paris ,","place":["France"]},{"name":"Facult\u00e9 de Sant\u00e9, Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]},{"name":"Inserm, Paris Cardiovascular Research Center , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Ginguay","sequence":"additional","affiliation":[{"name":"Clinical Chemistry Department, H\u00f4pital Cochin, AP-HP Paris Centre , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Roueff","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Transplantation, H\u00f4pital Europ\u00e9en Georges Pompidou (HEGP)-Assistance Publique H\u00f4pitaux de Paris (APHP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"2026060416352434800_aajaf021-B1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1073\/pnas.92.4.1013","article-title":"Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane","volume":"92","author":"Nielsen","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026060416352434800_aajaf021-B2","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s00394-017-1471-6","article-title":"Effect of increased water intake on plasma copeptin in healthy adults","volume":"57","author":"Lemetais","year":"2018","journal-title":"Eur J Nutr"},{"key":"2026060416352434800_aajaf021-B3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2369-11-26","article-title":"Abnormal function of the vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study","volume":"11","author":"Pedersen","year":"2010","journal-title":"BMC Nephrol"},{"key":"2026060416352434800_aajaf021-B4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3747\/pdi.2011.00026","article-title":"Clinical practice guidelines and recommendations on peritoneal dialysis adequacy 2011","volume":"31","author":"Blake","year":"2011","journal-title":"Perit Dial Int"},{"key":"2026060416352434800_aajaf021-B5","first-page":"33","article-title":"Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis","volume":"29","author":"Mori","year":"2013","journal-title":"Adv Perit Dial"},{"key":"2026060416352434800_aajaf021-B6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s10157-013-0883-8","article-title":"Tolvaptan increases urine and ultrafiltration volume for patients with oliguria undergoing peritoneal dialysis","volume":"18","author":"Iwahori","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"2026060416352434800_aajaf021-B7","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/ndt\/gfaa148","article-title":"Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a phase 2, double-blind, randomized, placebo-controlled trial","volume":"36","author":"Ogata","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026060416352434800_aajaf021-B8","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1152\/physrev.1983.63.4.1243","article-title":"Central nervous system mediators of vasopressin release","volume":"63","author":"Sklar","year":"1983","journal-title":"Physiol Rev"},{"key":"2026060416352434800_aajaf021-B9","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1172\/JCI107423","article-title":"Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma","volume":"52","author":"Robertson","year":"1973","journal-title":"J Clin Invest"},{"key":"2026060416352434800_aajaf021-B10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin Chem"},{"key":"2026060416352434800_aajaf021-B11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ekir.2017.01.006","article-title":"The effect of renal function and hemodialysis treatment on plasma vasopressin and copeptin levels","volume":"2","author":"Ettema","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2026060416352434800_aajaf021-B12","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s11255-019-02191-5","article-title":"Dialysate copeptin and peritoneal transport in incident peritoneal dialysis patients","volume":"51","author":"Fija\u0142kowski","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"2026060416352434800_aajaf021-B13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2026060416352434800_aajaf021-B14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/ckj\/sfab226","article-title":"Plasma copeptin is increased and associated with smaller kidney volume in young adults born very preterm","volume":"15","author":"Flahault","year":"2022","journal-title":"Clin Kidney J"},{"key":"2026060416352434800_aajaf021-B15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1053\/j.ajkd.2018.12.024","article-title":"Fasting urinary osmolality, CKD progression, and mortality: a prospective observational study","volume":"73","author":"Tabibzadeh","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026060416352434800_aajaf021-B16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000180511","article-title":"Physiology of antidiuretic hormone and the interrelationship between the hormone and the kidney","volume":"15","author":"Kurtzman","year":"1975","journal-title":"Nephron"},{"key":"2026060416352434800_aajaf021-B17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jacc.2009.01.076","article-title":"Incremental value of copeptin for rapid rule out of acute myocardial infarction","volume":"54","author":"Reichlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026060416352434800_aajaf021-B18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jacc.2008.03.050","article-title":"Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease","volume":"52","author":"Neuhold","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026060416352434800_aajaf021-B19","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/eurheartj\/ehp098","article-title":"C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study","volume":"30","author":"Voors","year":"2009","journal-title":"Eur Heart J"},{"key":"2026060416352434800_aajaf021-B20","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI108377","article-title":"Distribution, blood transport, and degradation of antidiuretic hormone in man","volume":"57","author":"Baumann","year":"1976","journal-title":"J Clin Invest"},{"key":"2026060416352434800_aajaf021-B21","doi-asserted-by":"publisher","first-page":"R365","DOI":"10.1152\/ajpregu.1986.251.2.R365","article-title":"Urinary and metabolic clearances of arginine vasopressin in normal subjects","volume":"251","author":"Moses","year":"1986","journal-title":"Am J Physiol"},{"key":"2026060416352434800_aajaf021-B22","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2215\/CJN.08690813","article-title":"Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients","volume":"9","author":"Zittema","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026060416352434800_aajaf021-B23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s10157-022-02220-1","article-title":"Altered arginine vasopressin-cyclic AMP-aquaporin 2 pathway in patients with chronic kidney disease","volume":"26","author":"Kakeshita","year":"2022","journal-title":"Clin Exp Nephrol"},{"key":"2026060416352434800_aajaf021-B24","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/ki.2009.325","article-title":"Vasopressin in chronic kidney disease: an elephant in the room?","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"key":"2026060416352434800_aajaf021-B25","doi-asserted-by":"publisher","first-page":"F973","DOI":"10.1152\/ajprenal.1990.258.4.F973","article-title":"Effect of water intake on the progression of chronic renal failure in the 5\/6 nephrectomized rat","volume":"258","author":"Bouby","year":"1990","journal-title":"Am J Physiol"},{"key":"2026060416352434800_aajaf021-B26","doi-asserted-by":"publisher","first-page":"i146","DOI":"10.1093\/ndt\/gfw391","article-title":"Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients","volume":"32","author":"Zittema","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2026060416352434800_aajaf021-B27","first-page":"30","article-title":"The vasopressin 2 receptor antagonist tolvaptan improves nutrition and inflammatory states in peritoneal dialysis patients with diabetes mellitus","volume":"31","author":"Hiramatsu","year":"2015","journal-title":"Adv Perit Dial"},{"key":"2026060416352434800_aajaf021-B28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1210\/endo.131.1.1535312","article-title":"Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain","volume":"131","author":"Ostrowski","year":"1992","journal-title":"Endocrinology"},{"key":"2026060416352434800_aajaf021-B29","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1073\/pnas.92.15.6783","article-title":"Extrapituitary expression of the rat V1b vasopressin receptor gene","volume":"92","author":"Lolait","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026060416352434800_aajaf021-B30","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1681\/ASN.2007070816","article-title":"Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli","volume":"19","author":"Azizi","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2026060416352434800_aajaf021-B31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1210\/jc.2008-1426","article-title":"Copeptin in the differential diagnosis of hyponatremia","volume":"94","author":"Fenske","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060416352434800_aajaf021-B32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fendo.2017.00120","article-title":"Role of the vasopressin\/apelin balance and potential use of metabolically stable apelin analogs in water metabolism disorders","volume":"8","author":"Flahault","year":"2017","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/1\/151\/66750192\/aajaf021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/1\/151\/66750192\/aajaf021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:35:27Z","timestamp":1780605327000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/1\/151\/8460046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,4]]},"published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajaf021","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]}}}